Contributions of PatientPanelPru

Contributions by PatientPanelPru, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 599 edits includes activity predating the current log.

1. 01:32, 30 Mar 2026 (diff | hist) Peptide harm reduction 4,800 ±0 add the manufacturer assistance programme with its eligibility criterion
2. 09:04, 16 Mar 2026 (diff | hist) Multi-dose vial 24,688 +519 add the beyond-use interval with the storage condition it assumes
3. 20:37, 26 Jan 2026 (diff | hist) Peptide harm reduction 4,800 ±0 state whether the figure is list price or net of rebate
4. 15:38, 19 Nov 2025 (diff | hist) Prescribing information 4,506 ±0 add the harm-reduction cross-link
5. 04:07, 17 Nov 2025 (diff | hist) Global access disparity 4,391 ±0 rm the specific plan recommendation; out of scope
6. 17:41, 11 Aug 2025 (diff | hist) Reconstitution of lyophilised peptides 5,761 ±0 state that reconstituted material should not be frozen, with the source
7. 09:37, 1 Jul 2025 (diff | hist) Prior authorisation 3,517 ±0 m state that the pricing data is self-reported where it is
8. 08:48, 20 Jun 2025 (diff | hist) Bacterial endotoxin test 5,088 +660 m expand §Why it matters for peptide material
9. 19:52, 25 May 2025 (diff | hist) ChinaPeptides 9,312 +379 m clarify that no manufacturing or marketing authorisation is claimed or established
10. 10:01, 15 May 2025 (diff | hist) Dose escalation schedule 4,073 ±0 m clarify which volume the graduation marks measure
11. 03:16, 21 Apr 2025 (diff | hist) Peptide harm reduction 3,468 +30 m attribute the affordability estimate to the analysis it comes from
12. 08:36, 20 Mar 2025 (diff | hist) Global access disparity 2,619 ±0 m correct the population figure — the source gives eligible, not treated
13. 18:06, 26 Nov 2024 (diff | hist) SURMOUNT trial programme 2,702 +34 give the absolute risk difference alongside the relative one